+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
IgA Nephropathy Market - Global Forecast 2026-2032- Product Image
IgA Nephropathy Market - Global Forecast 2026-2032- Product Image
Sale

IgA Nephropathy Market - Global Forecast 2026-2032

  • Report

  • 185 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6055585
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The IgA Nephropathy Market is projected to reach USD 1.46 Billion in 2026. It is expected to continue growing at a CAGR of 6.31%, reaching USD 2.11 Billion by 2032.

IgA Nephropathy: Executive Overview

IgA nephropathy is a kidney disease characterized by deposits of immunoglobulin A in the glomeruli, where blood filtration occurs. Its clinical course varies substantially, ranging from persistent blood in the urine to progressive loss of kidney function. Diagnosis commonly combines urinalysis, kidney-function assessment, serological evaluation, imaging where appropriate, and kidney biopsy when confirmation and risk assessment are required. Care increasingly emphasizes early detection, blood-pressure control, reduction of proteinuria, management of cardiovascular risk, and individualized decisions about immunomodulatory treatment.

Care Is Shifting Toward Earlier, Risk-Adapted Management

The management landscape is moving from late intervention toward structured risk assessment and earlier treatment of modifiable drivers of progression. Routine monitoring of estimated glomerular filtration rate, proteinuria, blood pressure, and hematuria supports more timely decisions. Clinical practice is also placing greater weight on supportive therapy, kidney-protective treatment, dietary and lifestyle measures, and shared decision-making, while reserving immunosuppression for carefully selected patients. Greater recognition of disease heterogeneity is encouraging approaches based on biopsy findings, clinical trajectory, comorbidities, and treatment tolerance.

Artificial Intelligence Strengthens Detection, Stratification, and Research

Artificial intelligence can support IgA nephropathy care by identifying abnormal urinalysis patterns, prioritizing patients for nephrology review, and assisting with interpretation of digital pathology and biopsy features. Machine-learning models may also help integrate longitudinal laboratory results, pathology, medication exposure, and clinical history to improve progression-risk stratification. Its cumulative value will depend on representative training data, transparent validation, clinician oversight, privacy safeguards, and prospective evidence showing that algorithmic support improves decisions rather than simply increasing alerts. AI should therefore complement, not replace, pathology expertise and clinical judgment.

Regional Insights: Uneven Diagnosis and Kidney-Care Capacity

North America combines comparatively broad access to nephrology, laboratory testing, biopsy services, and clinical research with persistent disparities linked to insurance, geography, and ethnicity. Europe benefits from established nephrology networks and guideline-driven care, although access and reimbursement differ across countries. Asia-Pacific contains highly varied screening practices, healthcare capacity, and disease-recognition pathways, with Japan, South Korea, Australia, and China contributing distinct clinical and research environments. Latin America faces uneven access to specialized diagnostics and follow-up, while Brazil and Mexico are important settings for strengthening referral pathways. In the Middle East, GCC systems generally have stronger specialist infrastructure than neighboring settings, but care remains heterogeneous. Africa continues to face major constraints in nephrology workforce availability, biopsy capacity, laboratory access, and continuity of chronic kidney disease management.

Group Insights: Diverse Health-System Priorities Shape Adoption

ASEAN members face differing levels of diagnostic capacity, reimbursement, and specialist availability, making scalable screening and referral models especially relevant. BRICS countries span substantial variation in healthcare infrastructure and research capability, creating opportunities for locally adapted protocols and stronger multicenter evidence. The European Union benefits from cross-border scientific collaboration and shared regulatory principles, but implementation remains influenced by national reimbursement and health-system structures. G7 members generally possess advanced research and specialist-care capabilities while continuing to address inequities and aging populations. GCC systems can support concentrated specialist programs and digital-care initiatives, whereas NATO members represent a broad set of health systems in which collaboration, interoperability, and continuity of care remain central priorities.

Country Insights: Distinct Clinical and System-Level Priorities

Australia and Canada must address geographic dispersion and equitable access to nephrology services. The United States has strong specialist, research, and pathology capabilities but faces pronounced differences in coverage and care access. Brazil, Mexico, India, and Russia need to strengthen earlier recognition, referral networks, biopsy availability, and long-term follow-up across diverse regions. China is expanding kidney-disease capacity while managing major variation between urban and rural services. Japan and South Korea have mature clinical systems with opportunities to refine risk-based monitoring and integrate digital tools. France, Germany, Italy, Spain, and the United Kingdom combine established nephrology expertise with country-specific reimbursement, referral, and service-delivery structures; priorities include consistent implementation and reducing delays in diagnosis and treatment.

Action Priorities for Leaders in IgA Nephropathy Care

Industry leaders should prioritize evidence generation that reflects real-world patient diversity and clinically meaningful outcomes, including kidney-function preservation, proteinuria reduction, safety, and quality of life. Diagnostic strategies should support earlier identification in primary care and coordinated referral to nephrology. Organizations should develop interoperable data systems linking laboratory, pathology, treatment, and outcome information while applying strict privacy and governance controls. Patient education should explain symptoms, monitoring, treatment adherence, blood-pressure management, and when to seek care. Partnerships with clinicians, health systems, patient organizations, and regulators can improve implementation, while access plans should address affordability, geographic barriers, and underdiagnosis.

Research Methodology: Evidence-Led Executive Synthesis

This executive summary uses the supplied disease scope and established clinical principles for IgA nephropathy, emphasizing diagnosis, disease monitoring, supportive care, treatment selection, digital health, and health-system access. Regional, group, and country observations are framed as qualitative comparisons of healthcare capacity, specialist availability, research activity, reimbursement variation, and diagnostic access rather than quantitative market claims. No estimates, market shares, forecasts, or company-specific assessments are included. Interpretations should be validated against current clinical guidelines, peer-reviewed studies, regulatory materials, and country-level health-system data before operational decisions are made.

Conclusion: Earlier Recognition and Coordinated Care Are Central

IgA nephropathy care is increasingly defined by earlier recognition, objective risk assessment, kidney-protective supportive management, and selective use of advanced therapies. Regional and national differences in diagnostic access, specialist capacity, reimbursement, and continuity of care will shape how quickly these practices become routine. Leaders can create durable impact by combining robust clinical evidence with practical referral pathways, responsible digital tools, patient-centered education, and equitable access strategies. Progress will depend on translating scientific advances into consistent, measurable care across diverse health systems.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. IgA Nephropathy Market, by Drug Class
7.1. Introduction
7.2. ACE Inhibitors
7.3. Angiotensin Receptor Blockers
7.4. Immunosuppressants
7.4.1. Azathioprine
7.4.2. Corticosteroids
7.4.3. Mycophenolate mofetil
8. IgA Nephropathy Market, by Treatment Type
8.1. Introduction
8.2. Immunosuppressive Therapy
8.3. Plasmapheresis
8.4. Renal Replacement Therapies
8.4.1. Dialysis
8.4.2. Kidney Transplantation
8.5. Supportive Care
9. IgA Nephropathy Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Subcutaneous
10. IgA Nephropathy Market, by Formulation
10.1. Introduction
10.2. Capsule
10.3. Injection
10.4. Oral Solution
10.5. Tablet
11. IgA Nephropathy Market, by Patient Type
11.1. Introduction
11.2. Adults
11.3. Elderly Patients
11.4. Pediatric Patients
12. IgA Nephropathy Market, by End User
12.1. Introduction
12.2. Academic & Research Institutes
12.3. Home Care Settings
12.4. Hospitals
12.5. Specialty Clinics/Nephrology Clinics
13. IgA Nephropathy Market, by Distribution Channel
13.1. Introduction
13.2. Offline Pharmacies
13.2.1. Hospital Pharmacies
13.2.2. Retail Pharmacies
13.3. Online Pharmacies
14. IgA Nephropathy Market, by Indication
14.1. Introduction
14.2. Primary IgA Nephropathy
14.3. Secondary IgA Nephropathy
15. IgA Nephropathy Market, by Region
15.1. Introduction
15.2. Asia-Pacific
15.3. North America
15.4. Latin America
15.5. Europe
15.6. Middle East
15.7. Africa
16. IgA Nephropathy Market, by Group
16.1. Introduction
16.2. ASEAN
16.3. GCC
16.4. European Union
16.5. BRICS
16.6. G7
16.7. NATO
17. IgA Nephropathy Market, by Country
17.1. Introduction
17.2. United States
17.3. Germany
17.4. China
17.5. United Kingdom
17.6. India
17.7. Japan
17.8. Russia
17.9. Brazil
17.10. Canada
17.11. Italy
17.12. Mexico
17.13. France
17.14. Spain
17.15. Australia
17.16. South Korea
18. Competitive Landscape
18.1. Market Share Analysis, 2025
18.2. Market Concentration Analysis, 2025
18.2.1. Concentration Ratio (CR)
18.2.2. Herfindahl Hirschman Index (HHI)
18.3. Recent Developments & Impact Analysis, 2025
18.4. Product Portfolio Analysis, 2025
18.5. Benchmarking Analysis, 2025
19. Company Profiles
19.1. Alnylam Pharmaceuticals, Inc.
19.2. Apellis Pharmaceuticals Inc.
19.3. Biogen Inc.
19.4. Boehringer Ingelheim International GmbH.
19.5. Calliditas Therapeutics AB by Asahi Kasei Corporation
19.6. ChemoCentryx, Inc. by Amgen Inc.
19.7. Eledon Pharmaceuticals Inc.
19.8. Eli Lilly and Company
19.9. F. Hoffmann-La Roche Ltd.
19.10. Ionis Pharmaceuticals Inc
19.11. Keymed Biosciences Inc.
19.12. Novartis AG
19.13. NovelMed Inc.
19.14. Novo Nordisk A/S.
19.15. Omeros Corporation
19.16. Otsuka Pharmaceutical Co. Ltd
19.17. Q32 Bio Inc.
19.18. Takeda Pharmaceutical Company
19.19. Travere Therapeutics Inc
19.20. Vera Therapeutics Inc
19.21. Vertex Pharmaceuticals Incorporated
20. Key Experts
LIST OF FIGURES
FIGURE 1. Global IgA Nephropathy Market, Years Considered for the Study
FIGURE 2. Global IgA Nephropathy Market, Research Design
FIGURE 3. Global IgA Nephropathy Market, Research Framework
FIGURE 4. Global IgA Nephropathy Market, Data Triangulation
FIGURE 5. Global IgA Nephropathy Market Size, 2017-2032 (USD Million)
FIGURE 6. Global IgA Nephropathy Market Size, by Drug Class, 2025 vs 2032 (%)
FIGURE 7. Global IgA Nephropathy Market Size, by Drug Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global IgA Nephropathy Market Size, by Treatment Type, 2025 vs 2032 (%)
FIGURE 9. Global IgA Nephropathy Market Size, by Treatment Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global IgA Nephropathy Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 11. Global IgA Nephropathy Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global IgA Nephropathy Market Size, by Formulation, 2025 vs 2032 (%)
FIGURE 13. Global IgA Nephropathy Market Size, by Formulation, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global IgA Nephropathy Market Size, by Patient Type, 2025 vs 2032 (%)
FIGURE 15. Global IgA Nephropathy Market Size, by Patient Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global IgA Nephropathy Market Size, by End User, 2025 vs 2032 (%)
FIGURE 17. Global IgA Nephropathy Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global IgA Nephropathy Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 19. Global IgA Nephropathy Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global IgA Nephropathy Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 21. Global IgA Nephropathy Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 22. Global IgA Nephropathy Market Size, by Region, 2025 vs 2032 (%)
FIGURE 23. Global IgA Nephropathy Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 24. Global IgA Nephropathy Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 25. Global IgA Nephropathy Market Size, by Country, 2025 vs 2032 (%)
FIGURE 26. Global IgA Nephropathy Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 27. Global IgA Nephropathy Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global IgA Nephropathy Market Segmentation & Coverage
TABLE 2. Global IgA Nephropathy Market Size, 2017-2032 (USD Million)
TABLE 3. Global IgA Nephropathy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 4. Global ACE Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global ACE Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global ACE Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Angiotensin Receptor Blockers Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Angiotensin Receptor Blockers Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Angiotensin Receptor Blockers Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Immunosuppressants Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Immunosuppressants Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Immunosuppressants Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Azathioprine Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Azathioprine Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Azathioprine Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Corticosteroids Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Corticosteroids Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Corticosteroids Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Mycophenolate mofetil Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Mycophenolate mofetil Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Mycophenolate mofetil Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global IgA Nephropathy Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 23. Global Immunosuppressive Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Immunosuppressive Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Immunosuppressive Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Plasmapheresis Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Plasmapheresis Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Plasmapheresis Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Renal Replacement Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Renal Replacement Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Renal Replacement Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Dialysis Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Dialysis Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Dialysis Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Kidney Transplantation Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Kidney Transplantation Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Kidney Transplantation Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Supportive Care Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Supportive Care Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Supportive Care Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global IgA Nephropathy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 42. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 43. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 44. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 45. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global IgA Nephropathy Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 52. Global Capsule Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Capsule Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Capsule Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Injection Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Injection Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Injection Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Oral Solution Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Oral Solution Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Oral Solution Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Tablet Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Tablet Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Tablet Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global IgA Nephropathy Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 65. Global Adults Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Adults Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Adults Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Elderly Patients Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Elderly Patients Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Elderly Patients Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Pediatric Patients Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Global Pediatric Patients Market Size, by Group, 2017-2032 (USD Million)
TABLE 73. Global Pediatric Patients Market Size, by Country, 2017-2032 (USD Million)
TABLE 74. Global IgA Nephropathy Market Size, by End User, 2017-2032 (USD Million)
TABLE 75. Global Academic & Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Global Academic & Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 77. Global Academic & Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 78. Global Home Care Settings Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Global Home Care Settings Market Size, by Group, 2017-2032 (USD Million)
TABLE 80. Global Home Care Settings Market Size, by Country, 2017-2032 (USD Million)
TABLE 81. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 83. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 84. Global Specialty Clinics/Nephrology Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Global Specialty Clinics/Nephrology Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 86. Global Specialty Clinics/Nephrology Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 87. Global IgA Nephropathy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 88. Global Offline Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Global Offline Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 90. Global Offline Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 91. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 92. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 93. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 94. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 95. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 96. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 97. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 98. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 99. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 100. Global IgA Nephropathy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 101. Global Primary IgA Nephropathy Market Size, by Region, 2017-2032 (USD Million)
TABLE 102. Global Primary IgA Nephropathy Market Size, by Group, 2017-2032 (USD Million)
TABLE 103. Global Primary IgA Nephropathy Market Size, by Country, 2017-2032 (USD Million)
TABLE 104. Global Secondary IgA Nephropathy Market Size, by Region, 2017-2032 (USD Million)
TABLE 105. Global Secondary IgA Nephropathy Market Size, by Group, 2017-2032 (USD Million)
TABLE 106. Global Secondary IgA Nephropathy Market Size, by Country, 2017-2032 (USD Million)
TABLE 107. Global IgA Nephropathy Market Size, by Region, 2017-2032 (USD Million)
TABLE 108. Asia-Pacific IgA Nephropathy Market Size, by Region, 2017-2032 (USD Million)
TABLE 109. Asia-Pacific IgA Nephropathy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 110. Asia-Pacific IgA Nephropathy Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 111. Asia-Pacific IgA Nephropathy Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 112. Asia-Pacific IgA Nephropathy Market Size, by Renal Replacement Therapies, 2017-2032 (USD Million)
TABLE 113. Asia-Pacific IgA Nephropathy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 114. Asia-Pacific IgA Nephropathy Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 115. Asia-Pacific IgA Nephropathy Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 116. Asia-Pacific IgA Nephropathy Market Size, by End User, 2017-2032 (USD Million)
TABLE 117. Asia-Pacific IgA Nephropathy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 118. Asia-Pacific IgA Nephropathy Market Size, by Offline Pharmacies, 2017-2032 (USD Million)
TABLE 119. Asia-Pacific IgA Nephropathy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 120. North America IgA Nephropathy Market Size, by Region, 2017-2032 (USD Million)
TABLE 121. North America IgA Nephropathy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 122. North America IgA Nephropathy Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 123. North America IgA Nephropathy Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 124. North America IgA Nephropathy Market Size, by Renal Replacement Therapies, 2017-2032 (USD Million)
TABLE 125. North America IgA Nephropathy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 126. North America IgA Nephropathy Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 127. North America IgA Nephropathy Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 128. North America IgA Nephropathy Market Size, by End User, 2017-2032 (USD Million)
TABLE 129. North America IgA Nephropathy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 130. North America IgA Nephropathy Market Size, by Offline Pharmacies, 2017-2032 (USD Million)
TABLE 131. North America IgA Nephropathy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 132. Latin America IgA Nephropathy Market Size, by Region, 2017-2032 (USD Million)
TABLE 133. Latin America IgA Nephropathy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 134. Latin America IgA Nephropathy Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 135. Latin America IgA Nephropathy Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 136. Latin America IgA Nephropathy Market Size, by Renal Replacement Therapies, 2017-2032 (USD Million)
TABLE 137. Latin America IgA Nephropathy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 138. Latin America IgA Nephropathy Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 139. Latin America IgA Nephropathy Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 140. Latin America IgA Nephropathy Market Size, by End User, 2017-2032 (USD Million)
TABLE 141. Latin America IgA Nephropathy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 142. Latin America IgA Nephropathy Market Size, by Offline Pharmacies, 2017-2032 (USD Million)
TABLE 143. Latin America IgA Nephropathy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 144. Europe IgA Nephropathy Market Size, by Region, 2017-2032 (USD Million)
TABLE 145. Europe IgA Nephropathy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 146. Europe IgA Nephropathy Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 147. Europe IgA Nephropathy Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 148. Europe IgA Nephropathy Market Size, by Renal Replacement Therapies, 2017-2032 (USD Million)
TABLE 149. Europe IgA Nephropathy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 150. Europe IgA Nephropathy Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 151. Europe IgA Nephropathy Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 152. Europe IgA Nephropathy Market Size, by End User, 2017-2032 (USD Million)
TABLE 153. Europe IgA Nephropathy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 154. Europe IgA Nephropathy Market Size, by Offline Pharmacies, 2017-2032 (USD Million)
TABLE 155. Europe IgA Nephropathy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 156. Middle East IgA Nephropathy Market Size, by Region, 2017-2032 (USD Million)
TABLE 157. Middle East IgA Nephropathy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 158. Middle East IgA Nephropathy Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 159. Middle East IgA Nephropathy Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 160. Middle East IgA Nephropathy Market Size, by Renal Replacement Therapies, 2017-2032 (USD Million)
TABLE 161. Middle East IgA Nephropathy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 162. Middle East IgA Nephropathy Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 163. Middle East IgA Nephropathy Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 164. Middle East IgA Nephropathy Market Size, by End User, 2017-2032 (USD Million)
TABLE 165. Middle East IgA Nephropathy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 166. Middle East IgA Nephropathy Market Size, by Offline Pharmacies, 2017-2032 (USD Million)
TABLE 167. Middle East IgA Nephropathy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 168. Africa IgA Nephropathy Market Size, by Region, 2017-2032 (USD Million)
TABLE 169. Africa IgA Nephropathy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 170. Africa IgA Nephropathy Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 171. Africa IgA Nephropathy Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 172. Africa IgA Nephropathy Market Size, by Renal Replacement Therapies, 2017-2032 (USD Million)
TABLE 173. Africa IgA Nephropathy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 174. Africa IgA Nephropathy Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 175. Africa IgA Nephropathy Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 176. Africa IgA Nephropathy Market Size, by End User, 2017-2032 (USD Million)
TABLE 177. Africa IgA Nephropathy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 178. Africa IgA Nephropathy Market Size, by Offline Pharmacies, 2017-2032 (USD Million)
TABLE 179. Africa IgA Nephropathy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 180. Global IgA Nephropathy Market Size, by Group, 2017-2032 (USD Million)
TABLE 181. ASEAN IgA Nephropathy Market Size, by Group, 2017-2032 (USD Million)
TABLE 182. ASEAN IgA Nephropathy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 183. ASEAN IgA Nephropathy Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 184. ASEAN IgA Nephropathy Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 185. ASEAN IgA Nephropathy Market Size, by Renal Replacement Therapies, 2017-2032 (USD Million)
TABLE 186. ASEAN IgA Nephropathy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 187. ASEAN IgA Nephropathy Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 188. ASEAN IgA Nephropathy Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 189. ASEAN IgA Nephropathy Market Size, by End User, 2017-2032 (USD Million)
TABLE 190. ASEAN IgA Nephropathy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 191. ASEAN IgA Nephropathy Market Size, by Offline Pharmacies, 2017-2032 (USD Million)
TABLE 192. ASEAN IgA Nephropathy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 193. GCC IgA Nephropathy Market Size, by Group, 2017-2032 (USD Million)
TABLE 194. GCC IgA Nephropathy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 195. GCC IgA Nephropathy Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 196. GCC IgA Nephropathy Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 197. GCC IgA Nephropathy Market Size, by Renal Replacement Therapies, 2017-2032 (USD Million)
TABLE 198. GCC IgA Nephropathy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 199. GCC IgA Nephropathy Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 200. GCC IgA Nephropathy Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 201. GCC IgA Nephropathy Market Size, by End User, 2017-2032 (USD Million)
TABLE 202. GCC IgA Nephropathy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 203. GCC IgA Nephropathy Market Size, by Offline Pharmacies, 2017-2032 (USD Million)
TABLE 204. GCC IgA Nephropathy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 205. European Union IgA Nephropathy Market Size, by Group, 2017-2032 (USD Million)
TABLE 206. European Union IgA Nephropathy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 207. European Union IgA Nephropathy Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 208. European Union IgA Nephropathy Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 209. European Union IgA Nephropathy Market Size, by Renal Replacement Therapies, 2017-2032 (USD Million)
TABLE 210. European Union IgA Nephropathy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 211. European Union IgA Nephropathy Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 212. European Union IgA Nephropathy Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 213. European Union IgA Nephropathy Market Size, by End User, 2017-2032 (USD Million)
TABLE 214. European Union IgA Nephropathy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 215. European Union IgA Nephropathy Market Size, by Offline Pharmacies, 2017-2032 (USD Million)
TABLE 216. European Union IgA Nephropathy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 217. BRICS IgA Nephropathy Market Size, by Group, 2017-2032 (USD Million)
TABLE 218. BRICS IgA Nephropathy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 219. BRICS IgA Nephropathy Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 220. BRICS IgA Nephropathy Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 221. BRICS IgA Nephropathy Market Size, by Renal Replacement Therapies, 2017-2032 (USD Million)
TABLE 222. BRICS IgA Nephropathy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 223. BRICS IgA Nephropathy Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 224. BRICS IgA Nephropathy Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 225. BRICS IgA Nephropathy Market Size, by End User, 2017-2032 (USD Million)
TABLE 226. BRICS IgA Nephropathy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 227. BRICS IgA Nephropathy Market Size, by Offline Pharmacies, 2017-2032 (USD Million)
TABLE 228. BRICS IgA Nephropathy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 229. G7 IgA Nephropathy Market Size, by Group, 2017-2032 (USD Million)
TABLE 230. G7 IgA Nephropathy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 231. G7 IgA Nephropathy Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 232. G7 IgA Nephropathy Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 233. G7 IgA Nephropathy Market Size, by Renal Replacement Therapies, 2017-2032 (USD Million)
TABLE 234. G7 IgA Nephropathy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 235. G7 IgA Nephropathy Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 236. G7 IgA Nephropathy Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 237. G7 IgA Nephropathy Market Size, by End User, 2017-2032 (USD Million)
TABLE 238. G7 IgA Nephropathy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 239. G7 IgA Nephropathy Market Size, by Offline Pharmacies, 2017-2032 (USD Million)
TABLE 240. G7 IgA Nephropathy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 241. NATO IgA Nephropathy Market Size, by Group, 2017-2032 (USD Million)
TABLE 242. NATO IgA Nephropathy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 243. NATO IgA Nephropathy Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 244. NATO IgA Nephropathy Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 245. NATO IgA Nephropathy Market Size, by Renal Replacement Therapies, 2017-2032 (USD Million)
TABLE 246. NATO IgA Nephropathy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 247. NATO IgA Nephropathy Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 248. NATO IgA Nephropathy Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 249. NATO IgA Nephropathy Market Size, by End User, 2017-2032 (USD Million)
TABLE 250. NATO IgA Nephropathy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 251. NATO IgA Nephropathy Market Size, by Offline Pharmacies, 2017-2032 (USD Million)
TABLE 252. NATO IgA Nephropathy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 253. Global IgA Nephropathy Market Size, by Country, 2017-2032 (USD Million)
TABLE 254. United States IgA Nephropathy Market Size, 2017-2032 (USD Million)
TABLE 255. United States IgA Nephropathy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 256. United States IgA Nephropathy Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 257. United States IgA Nephropathy Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 258. United States IgA Nephropathy Market Size, by Renal Replacement Therapies, 2017-2032 (USD Million)
TABLE 259. United States IgA Nephropathy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 260. United States IgA Nephropathy Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 261. United States IgA Nephropathy Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 262. United States IgA Nephropathy Market Size, by End User, 2017-2032 (USD Million)
TABLE 263. United States IgA Nephropathy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 264. United States IgA Nephropathy Market Size, by Offline Pharmacies, 2017-2032 (USD Million)
TABLE 265. United States IgA Nephropathy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 266. Germany IgA Nephropathy Market Size, 2017-2032 (USD Million)
TABLE 267. Germany IgA Nephropathy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 268. Germany IgA Nephropathy Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 269. Germany IgA Nephropathy Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 270. Germany IgA Nephropathy Market Size, by Renal Replacement Therapies, 2017-2032 (USD Million)
TABLE 271. Germany IgA Nephropathy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 272. Germany IgA Nephropathy Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 273. Germany IgA Nephropathy Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 274. Germany IgA Nephropathy Market Size, by End User, 2017-2032 (USD Million)
TABLE 275. Germany IgA Nephropathy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 276. Germany IgA Nephropathy Market Size, by Offline Pharmacies, 2017-2032 (USD Million)
TABLE 277. Germany IgA Nephropathy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 278. China IgA Nephropathy Market Size, 2017-2032 (USD Million)
TABLE 279. China IgA Nephropathy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 280. China IgA Nephropathy Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 281. China IgA Nephropathy Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 282. China IgA Nephropathy Market Size, by Renal Replacement Therapies, 2017-2032 (USD Million)
TABLE 283. China IgA Nephropathy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 284. China IgA Nephropathy Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 285. China IgA Nephropathy Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 286. China IgA Nephropathy Market Size, by End User, 2017-2032 (USD Million)
TABLE 287. China IgA Nephropathy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 288. China IgA Nephropathy Market Size, by Offline Pharmacies, 2017-2032 (USD Million)
TABLE 289. China IgA Nephropathy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 290. United Kingdom IgA Nephropathy Market Size, 2017-2032 (USD Million)
TABLE 291. United Kingdom IgA Nephropathy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 292. United Kingdom IgA Nephropathy Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 293. United Kingdom IgA Nephropathy Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 294. United Kingdom IgA Nephropathy Market Size, by Renal Replacement Therapies, 2017-2032 (USD Million)
TABLE 295. United Kingdom IgA Nephropathy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 296. United Kingdom IgA Nephropathy Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 297. United Kingdom IgA Nephropathy Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 298. United Kingdom IgA Nephropathy Market Size, by End User, 2017-2032 (USD Million)
TABLE 299. United Kingdom IgA Nephropathy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 300. United Kingdom IgA Nephropathy Market Size, by Offline Pharmacies, 2017-2032 (USD Million)
TABLE 301. United Kingdom IgA Nephropathy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 302. India IgA Nephropathy Market Size, 2017-2032 (USD Million)
TABLE 303. India IgA Nephropathy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 304. India IgA Nephropathy Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 305. India IgA Nephropathy Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 306. India IgA Nephropathy Market Size, by Renal Replacement Therapies, 2017-2032 (USD Million)
TABLE 307. India IgA Nephropathy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 308. India IgA Nephropathy Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 309. India IgA Nephropathy Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 310. India IgA Nephropathy Market Size, by End User, 2017-2032 (USD Million)
TABLE 311. India IgA Nephropathy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 312. India IgA Nephropathy Market Size, by Offline Pharmacies, 2017-2032 (USD Million)
TABLE 313. India IgA Nephropathy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 314. Japan IgA Nephropathy Market Size, 2017-2032 (USD Million)
TABLE 315. Japan IgA Nephropathy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 316. Japan IgA Nephropathy Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 317. Japan IgA Nephropathy Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 318. Japan IgA Nephropathy Market Size, by Renal Replacement Therapies, 2017-2032 (USD Million)
TABLE 319. Japan IgA Nephropathy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 320. Japan IgA Nephropathy Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 321. Japan IgA Nephropathy Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 322. Japan IgA Nephropathy Market Size, by End User, 2017-2032 (USD Million)
TABLE 323. Japan IgA Nephropathy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 324. Japan IgA Nephropathy Market Size, by Offline Pharmacies, 2017-2032 (USD Million)
TABLE 325. Japan IgA Nephropathy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 326. Russia IgA Nephropathy Market Size, 2017-2032 (USD Million)
TABLE 327. Russia IgA Nephropathy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 328. Russia IgA Nephropathy Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 329. Russia IgA Nephropathy Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 330. Russia IgA Nephropathy Market Size, by Renal Replacement Therapies, 2017-2032 (USD Million)
TABLE 331. Russia IgA Nephropathy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 332. Russia IgA Nephropathy Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 333. Russia IgA Nephropathy Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 334. Russia IgA Nephropathy Market Size, by End User, 2017-2032 (USD Million)
TABLE 335. Russia IgA Nephropathy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 336. Russia IgA Nephropathy Market Size, by Offline Pharmacies, 2017-2032 (USD Million)
TABLE 337. Russia IgA Nephropathy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 338. Brazil IgA Nephropathy Market Size, 2017-2032 (USD Million)
TABLE 339. Brazil IgA Nephropathy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 340. Brazil IgA Nephropathy Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 341. Brazil IgA Nephropathy Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 342. Brazil IgA Nephropathy Market Size, by Renal Replacement Therapies, 2017-2032 (USD Million)
TABLE 343. Brazil IgA Nephropathy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 344. Brazil IgA Nephropathy Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 345. Brazil IgA Nephropathy Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 346. Brazil IgA Nephropathy Market Size, by End User, 2017-2032 (USD Million)
TABLE 347. Brazil IgA Nephropathy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 348. Brazil IgA Nephropathy Market Size, by Offline Pharmacies, 2017-2032 (USD Million)
TABLE 349. Brazil IgA Nephropathy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 350. Canada IgA Nephropathy Market Size, 2017-2032 (USD Million)
TABLE 351. Canada IgA Nephropathy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 352. Canada IgA Nephropathy Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 353. Canada IgA Nephropathy Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 354. Canada IgA Nephropathy Market Size, by Renal Replacement Therapies, 2017-2032 (USD Million)
TABLE 355. Canada IgA Nephropathy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 356. Canada IgA Nephropathy Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 357. Canada IgA Nephropathy Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 358. Canada IgA Nephropathy Market Size, by End User, 2017-2032 (USD Million)
TABLE 359. Canada IgA Nephropathy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 360. Canada IgA Nephropathy Market Size, by Offline Pharmacies, 2017-2032 (USD Million)
TABLE 361. Canada IgA Nephropathy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 362. Italy IgA Nephropathy Market Size, 2017-2032 (USD Million)
TABLE 363. Italy IgA Nephropathy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 364. Italy IgA Nephropathy Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 365. Italy IgA Nephropathy Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 366. Italy IgA Nephropathy Market Size, by Renal Replacement Therapies, 2017-2032 (USD Million)
TABLE 367. Italy IgA Nephropathy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 368. Italy IgA

Companies Mentioned

  • Alnylam Pharmaceuticals, Inc.
  • Apellis Pharmaceuticals Inc.
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH.
  • Calliditas Therapeutics AB by Asahi Kasei Corporation
  • ChemoCentryx, Inc. by Amgen Inc.
  • Eledon Pharmaceuticals Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Ionis Pharmaceuticals Inc
  • Keymed Biosciences Inc.
  • Novartis AG
  • NovelMed Inc.
  • Novo Nordisk A/S.
  • Omeros Corporation
  • Otsuka Pharmaceutical Co. Ltd
  • Q32 Bio Inc.
  • Takeda Pharmaceutical Company
  • Travere Therapeutics Inc
  • Vera Therapeutics Inc
  • Vertex Pharmaceuticals Incorporated

Related Topics

Related Reports

IgA Nephropathy (Berger's Disease): Market View - Product Image

IgA Nephropathy (Berger's Disease): Market View

  • Report
  • 115 Pages
  • Global
From
Diabetic nephropathy Market - Global Forecast 2026-2032 - Product Image

Diabetic nephropathy Market - Global Forecast 2026-2032

  • Report
  • 186 Pages
  • Global
From
Diabetic Nephropathy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Diabetic Nephropathy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 140 Pages
  • Global
From
Diagnostic Pathology: Kidney Diseases. Edition No. 3 - Product Image

Diagnostic Pathology: Kidney Diseases. Edition No. 3

  • Book
Rare Kidney Diseases Market Report 2026 - Product Image

Rare Kidney Diseases Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.